Phathom Pharmaceuticals (PHAT) Retained Earnings (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Retained Earnings for 9 consecutive years, with -$1.5 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Retained Earnings fell 6.91% year-over-year to -$1.5 billion; the TTM figure through Jun 2026 stood at -$1.5 billion (down 6.91% YoY), while the FY2025 annual figure was -$1.5 billion, down 17.52% from the prior year.
• Retained Earnings retreated to -$1.5 billion in Q2 2026 per PHAT's latest filing, from -$1.5 billion in the prior quarter.
• Across five years, Retained Earnings topped out at -$570.0 million in Q1 2022 and bottomed at -$1.5 billion in Q2 2026.
• Historically, Retained Earnings has averaged -$1.1 billion across 5 years, with a median of -$1.1 billion in 2024.
• Annual changes were most pronounced in 2024 — Retained Earnings sank 39.98% — and 2026, when it retreated 6.91%.
• Phathom Pharmaceuticals' Retained Earnings stood at -$727.1 million in 2022, then dropped by 27.73% to -$928.7 million in 2023, then sank by 36.0% to -$1.3 billion in 2024, then retreated by 17.52% to -$1.5 billion in 2025, then retreated by 3.23% to -$1.5 billion in 2026.
• Business Quant data shows PHAT's Retained Earnings at -$1.5 billion in Q2 2026, -$1.5 billion in Q1 2026, and -$1.5 billion in Q4 2025.